TY - JOUR
T1 - Discontinuation of alprazolam treatment in panic patients
AU - Fyer, A. J.
AU - Liebowitz, M. R.
AU - Gorman, J. M.
AU - Campeas, R.
AU - Levin, A.
AU - Davies, S. O.
AU - Goetz, D.
AU - Klein, D. F.
PY - 1987
Y1 - 1987
N2 - Alprazolam treatment was tapered in 17 panic patients at a rate of 10% of the starting dose every 3 days. Only four subjects completed withdrawal on schedule (4-5 weeks); four additional subjects discontinued treatment in 7-13 weeks. During withdrawal 15 patients had recurrent or increased panic attacks and nine had significant new withdrawal symptoms. Most common among the latter were malaise, weakness, insomnia, tachycardia, lightheadedness, and dizziness. None had seizures, psychosis, or significant neurological or EEG abnormalities. Results indicate that relapse and withdrawal are important considerations in the choice of alprazolam treatment for panic attacks.
AB - Alprazolam treatment was tapered in 17 panic patients at a rate of 10% of the starting dose every 3 days. Only four subjects completed withdrawal on schedule (4-5 weeks); four additional subjects discontinued treatment in 7-13 weeks. During withdrawal 15 patients had recurrent or increased panic attacks and nine had significant new withdrawal symptoms. Most common among the latter were malaise, weakness, insomnia, tachycardia, lightheadedness, and dizziness. None had seizures, psychosis, or significant neurological or EEG abnormalities. Results indicate that relapse and withdrawal are important considerations in the choice of alprazolam treatment for panic attacks.
UR - http://www.scopus.com/inward/record.url?scp=0023112126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023112126&partnerID=8YFLogxK
U2 - 10.1176/ajp.144.3.303
DO - 10.1176/ajp.144.3.303
M3 - Article
AN - SCOPUS:0023112126
SN - 0002-953X
VL - 144
SP - 303
EP - 308
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 3
ER -